iVAC-CLL01: Patient-individualized Peptide Vaccination After First Line Therapy of CLL
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
The aim of this study is to induce a peptide-specific immune response in CLL patients by
multi-peptide vaccination with a patient-individualized peptide cocktail.
Phase:
Phase 2
Details
Lead Sponsor:
University Hospital Tuebingen
Collaborators:
Katharinenhospital Stuttgart Klinikum Stuttgart Marienhospital Stuttgart Robert Bosch Gesellschaft für Medizinische Forschung mbH